Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arun A Azad

Showing results (1-10 of 140) with videos related to

Pageof 14
Sort By:
European Urology|December 17, 2025
Re: Niraparib and Abiraterone Acetate plus Prednisone for HRR-deficient Metastatic Castration-sensitive Prostate Cancer: A Randomized Phase 3 TrialJane McKenzie, Arun A Azad
Translational Andrology and Urology|February 9, 2026
Pembrolizumab in metastatic hormone-sensitive prostate cancer: lessons from the negative KEYNOTE-991 trialJane McKenzie, Arun A Azad
Current Opinion in Urology|May 27, 2020
Chemotherapy, not androgen receptor-targeted therapy should be used upfront for metastatic hormone-sensitive prostate cancer. PRO: docetaxel chemotherapy should be the default consideration in metastatic hormone-sensitive prostate cancerEdmond M Kwan, Arun A Azad
European Urology|April 13, 2015
Reply to Kevin Lu's letter to the editor re: Arun A. Azad, Bernhard J. Eigl, Raya Leibowitz-Amit, et al. outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status. Eur Urol 2015;67:441-7Arun A Azad, Kim N Chi
European Urology|November 12, 2013
Evaluation of prostate-specific antigen response following cessation of abiraterone acetate: is there evidence for a withdrawal syndrome?Arun A Azad, Bernhard J Eigl
World Journal of Urology|August 27, 2022
Future directions in systemic treatment of metastatic hormone-sensitive prostate cancerKenneth Chen, Louise Kostos, Arun A Azad
Drugs|July 26, 2024
Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate CancerLouise Kostos, Ben Tran, Arun A Azad
Cancer Cell|November 4, 2022
KIT as a therapeutic target in neuroendocrine prostate cancerArun A Azad, Louise Kostos, Neeraj Agarwal
European Urology Oncology|July 22, 2022
Double or Triple Trouble in Metastatic Hormone-sensitive Prostate Cancer?Louise Kostos, Declan G Murphy, Arun A Azad
Cellular Oncology (Dordrecht, Netherlands)|October 28, 2018
Cell-free DNA in cancer: current insightsHeidi Fettke, Edmond M Kwan, Arun A Azad
Pageof 14

Showing results (1-10 of 140) with videos related to

Sort By:
Pageof 14
European Urology|December 17, 2025
Re: Niraparib and Abiraterone Acetate plus Prednisone for HRR-deficient Metastatic Castration-sensitive Prostate Cancer: A Randomized Phase 3 TrialJane McKenzie, Arun A Azad
Translational Andrology and Urology|February 9, 2026
Pembrolizumab in metastatic hormone-sensitive prostate cancer: lessons from the negative KEYNOTE-991 trialJane McKenzie, Arun A Azad
Current Opinion in Urology|May 27, 2020
Chemotherapy, not androgen receptor-targeted therapy should be used upfront for metastatic hormone-sensitive prostate cancer. PRO: docetaxel chemotherapy should be the default consideration in metastatic hormone-sensitive prostate cancerEdmond M Kwan, Arun A Azad
European Urology|April 13, 2015
Reply to Kevin Lu's letter to the editor re: Arun A. Azad, Bernhard J. Eigl, Raya Leibowitz-Amit, et al. outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status. Eur Urol 2015;67:441-7Arun A Azad, Kim N Chi
European Urology|November 12, 2013
Evaluation of prostate-specific antigen response following cessation of abiraterone acetate: is there evidence for a withdrawal syndrome?Arun A Azad, Bernhard J Eigl
World Journal of Urology|August 27, 2022
Future directions in systemic treatment of metastatic hormone-sensitive prostate cancerKenneth Chen, Louise Kostos, Arun A Azad
Drugs|July 26, 2024
Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate CancerLouise Kostos, Ben Tran, Arun A Azad
Cancer Cell|November 4, 2022
KIT as a therapeutic target in neuroendocrine prostate cancerArun A Azad, Louise Kostos, Neeraj Agarwal
European Urology Oncology|July 22, 2022
Double or Triple Trouble in Metastatic Hormone-sensitive Prostate Cancer?Louise Kostos, Declan G Murphy, Arun A Azad
Cellular Oncology (Dordrecht, Netherlands)|October 28, 2018
Cell-free DNA in cancer: current insightsHeidi Fettke, Edmond M Kwan, Arun A Azad
Pageof 14